Oridion Capnography Revenue and Competitors

Oridion is a medical device company that has developed and patented unique technologies in the fields of patient monitoring and breath testing. The Company has sales activities in the US, Europe, Japan and Israel. The Company employs 111 people worldwide. Oridion's operations are in Israel and marketing and sales are in the United States, Europe and Japan. Oridion was the first Israeli company to receive a CE mark (approval to self-certify) in the medical device field. 2. What is Oridion's core business? Oridion is a global medical device company with patented technologies using breath samples in respiratory care monitoring and point-of-care diagnostics for both acute and non-acute settings. Oridion operates two business units: The Capnography Business Unit promotes the enhancement of patient safety monitoring by developing proprietary medical devices and consumables for the measurement of carbon dioxide in human breath. Oridion's capnography products determine the status and adequacy of a patient's ventilation in all patient environments. The Breath Testing Business Unit develops proprietary medical devices and consumables used in the non-invasive diagnosis of the status of a patient's internal organs. Oridion's Breath Testing device enables the physician to diagnose and prescribe treatment for patients in a single office visit. 3. What is Oridion's potential business growth? Oridion has designed its business line of patient safety monitors so that it can be used with all patients, both intubated and non-intubated in all environments, including procedural sedation. With the migration of procedures from the traditional operating theaters and intensive care units to surgical centers due to cost-containment efforts, technology development and new clinical standards, the trend towards procedural sedation monitoring is expected to result in double-digit growth rates. Also, Oridion monitors are designed to use a single patient circuit with each procedure. These proprietary circuits enable the use of the monitors in different clinical environments and are the self-sustaining engine that provides sales and gross margin growth as the installed base of monitors grow. Oridion developed the BreathID® multi-test platform system. The BreathID® is non-invasive and provides quick results that can be used for diagnosis and disease management for an array of organ-specific medical conditions in the physician-patient environment. The business model is also based on the use of single patient proprietary circuits (nasal cannula). As in the capnography business, the growth in the installed base will generate a follow-up demand in circuits with high gross margins. The addition of new tests to this business line will result in the acceleration of sales and earnings. 4. Who are Oridion's customers in the Capnography monitoring business line? The technological edge offered by Microstream® technology has enabled Oridion to take its place as a market leader in capnography. Oridion has signed OEM development and distribution agreements with global leaders of monitoring systems including Medtronic, Philips Medical Systems( formerly Agilent Technologies Healthcare Solutions Group), Draeger Medical (A Draeger and Siemens Company)Datascope, Nellcor (Tyco) and more. These alliances will result in an increased installed base of capnography units supporting strong growth in the proprietary consumables business. 5. Explain Oridion's Breath Testing Diagnostics system? The Oridion BreathID® is the only multi-test platform device enabling diagnosis and monitoring of multiple functional GI disorders. Based on Oridion's patented Microstream® technology, the BreathID® is an ideal, user friendly tool for GI testing, currently for such common disorders as H. pylori, and Gastric Emptying Rate and Liver Function. The BreathID® is a sophisticated on-line breath collection and analysis system for real-time breath analysis. With single button operation, easy-to-follow on-screen instructions, internal quality control mechanism, and self-calibration, BreathID® is ideal for the office environment. 6. What is Oridion's business model for its Breath Testing business? The business model for the BreathID® is also based on the use of single patient proprietary circuits. As in the capnography business, the growth in the installed base will generate a follow-up demand in circuits with high gross margins. The addition of this new business line will result in the acceleration of sales and earnings. H. pylori is estimated to affect approximately 275 million people in developed countries, and industry consultants estimate the market potential of the H. pylori breath test to reach towards US$500M in the U.S. alone. Japan and Europe also present a large market potential. To support our business model, we have have a Breath Testing subsidiary in the U.S. and a business unit in Japan. 7. Who are Oridion's competitors - in Europe and worldwide? In many ways, Oridion does not have any competitors because of our unique, patented technology. Former technology competitors such as Philips Medical Systems (formely Agilent Technologies Healthcare Solutions Group) have incorporated Oridion technology into their monitoring systems. Many of our previous competitors are today our partners or customers. 8. What is Oridion's proprietary and patented technology? Molecular Correlation Spectroscopy (marketed under the Microstream® trademark) is Oridion's patented fingerprinting technology. The patent is based on the fingerprinting of CO2 in exhaled breath. Employing this proprietary technology, the Company has made critical advances in the two distinct fields of capnography monitoring and breath testing. Oridion currently is the owner or has the exclusive rights to twelve different patents, protecting the Company's technology used in the vital components of its products, in all of the Company's key markets including the U.S., Europe, Japan and Israel. In addition to its registered patents, Oridion has numerous patent applications pending worldwide.